Skip to search formSkip to main contentSkip to account menu

Tartrate-Resistant Acid Phosphatase Type 5b, human

Known as: EC 3.1.3.2, Tartrate-Resistant Acid Phosphatase-5b, TRACP-5b 
Tartrate-resistant acid phosphatase type 5b (325 aa, ~37 kDa) is encoded by the human ACP5 gene. This protein is involved in acid phosphatase… 
National Institutes of Health

Related topics

Related topics

15 relations
ACP5 geneACP5 protein, humanBone remodelingDephosphorylation

Broader (1)

tartrate-resistant acid phosphatase

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions
Osteoporosis is a major concern all over the world. With aging, a gradual loss of bone mass results in osteopenia and… 
Highly Cited
2014
Highly Cited
2014
Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.
BACKGROUND AND OBJECTIVES Use of bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA) is controversial for… 
Highly Cited
2014
Highly Cited
2014
Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
Highly Cited
2011
Highly Cited
2011
Mechanism of action and morphologic changes in the alveolar bone in response to selective alveolar decortication-facilitated tooth movement.
Highly Cited
2011
Highly Cited
2011
Comparative effects of dried plum and dried apple on bone in postmenopausal women.
Aside from existing drug therapies, certain lifestyle and nutritional factors are known to reduce the risk of osteoporosis. Among… 
Highly Cited
2009
Highly Cited
2009
Single‐Dose, Randomized, Double‐Blind, Placebo‐Controlled Study of ACE‐011 (ActRIIA‐IgG1) in Postmenopausal Women
The effects of ACE‐011 on safety, pharmacokinetics, and bone biomarkers were evaluated in healthy, postmenopausal women. Our data… 
Highly Cited
2007
Highly Cited
2007
Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the…
The role of receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG) system, and osteopontin (OPN) was… 
Highly Cited
2006
Highly Cited
2006
Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
The effect of bortezomib on bone remodelling was evaluated in 34 relapsed myeloma patients. At baseline, patients had increased… 
Highly Cited
2004
Highly Cited
2004
Role of receptor activator of nuclear factor‐kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1‐alpha (MIP‐1a) in monoclonal gammopathy of undetermined significance (MGUS)
The aim of this study was to evaluate the role of markers of bone remodelling, and osteoclast activation/function in patients… 
Highly Cited
2003
Highly Cited
2003
Pamidronate is an effective treatment for osteoporosis in patients with beta‐thalassaemia
Summary.  Osteoporosis in beta‐thalassaemia is multifactorial; increased osteoclast function seems to play an important role in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)